Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d; "We are very pleased to enter this partnership with ThromboGenics and BioInvent. This novel antibody, TB-403 has the potential to play a major role in the treatment of cancer and we are committed to driving ahead with its development. In addition, we look forward to developing a strong working relationship with ThromboGenics and BioInvent."

Notes to Editors:

About TB-403

TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB) at the University of Leuven, Belgium, where the therapeutic potential of anti-PlGF agents to treat cancer was first developed in the laboratory of Prof. Peter Carmeliet.

Angiogenesis inhibitors such as TB-403 are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutrients. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. PlGF is a homologue of VEGF and current preclinical evidence suggests that it may not affect normal, physiological angiogenesis and is predominantly involved in angiogenesis of malignant tissue.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF). ThromboGenics and BioInvent have recently signed a license agreement with Roche for TB-403 worth EUR 500 million plus royalties. TB-403 is scheduled to enter a Phase Ib clinical t
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... IAC Industries wants to share with you the ... to set up and furnish a research lab knowing that ... a year’s time. How does a company make choices in ... What is efficient and cost-effective? , The solution was ... The planners at DisperSol determined that the concept of modular ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 In late 2012, ... to speak to doctors in China about Appearance Medicine ... NZ, this was her first trip to lecture in China, ... visited Guangzhou and Fuzhou, home to 12 and 7 million ... is very high at this point in time. As Dr. ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
(Date:5/16/2013)... , May 16, 2013 ... research report is available in its ... Cardiac Biomarkers for Acute Coronary Syndromes ... http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Acute Coronary Syndromes - APAC Analysis ...
Breaking Biology Technology:New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8
... Aug. 30, 2011 Amnis Corporation, a manufacturer of advanced ... acquired by EMD Millipore, the Life Science division of Merck ... and closing is expected to take place in the fourth ... disclosed. Amnis generated sales of USD 14 ...
... new strain of yeast that converts seaweed into biofuel in ... process that,s important outside the Corn Belt, said Yong-Su Jin, ... a faculty member in its Institute for Genomic Biology. ... galactose simultaneously, which makes the process much more efficient," Jin ...
... OH The American Ceramic Society (ACerS) today announced ... Members. David B. Marshall and Koichi Niihari are ... the highest honor accorded members of ACerS. The award ... to the ceramic and glass profession. "The Society,s ...
Cached Biology Technology:Amnis Acquired by EMD Millipore - Expands Growth Potential 2Amnis Acquired by EMD Millipore - Expands Growth Potential 3IllinoisUC Berkeley discovery turns seaweed into biofuel in half the time 2The American Ceramic Society selects Marshall, Niihara as 2011 Distinguish Life Members 2
(Date:5/16/2013)... -- Injectable nanoparticles developed at MIT may someday ... diabetes to constantly monitor their blood-sugar levels and ... designed to sense glucose levels in the body ... insulin, thereby replacing the function of pancreatic islet ... 1 diabetes. Ultimately, this type of system could ...
(Date:5/16/2013)... with ,scissor hand-like, claws in fossil records and has ... , The 505 million year old fossil called ... a distant ancestor of lobsters and scorpions, was named ... as Edward Scissorhands - a movie about an artificial ... for hands. , Kooteninchela deppi is ...
(Date:5/16/2013)... a conservationist working in Cameroon and the manager of ... been awarded the prestigious Whitley award. The Whitley ... "The Green Oscars" because it celebrates the extraordinary achievements ... developing countries. Abwe was selected for the award ... Cameroon,s Ebo Forest and its wildlife inhabitants., HRH The ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Actor Johnny Depp immortalized in ancient fossil find 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... Michael Courtney has identified a new molecular pathway in ... of brain cells, which in turn plays an important ... disease, epilepsy and stroke. Courtney and his team, based ... of Kuopio, joined forces with Docent Eleanor Coffey's team ...
... on the amount of salt in their diet could reduce their ... report on bmj.com today. , Researchers in Boston also ... death from cardiovascular disease by up to a fifth. ... to the heart or arteries, for example a stroke or heart ...
... Scientists at The University of Manchester believe injections of ... surgery in the treatment of chronic lower back pain. ... and Professor Tony Freemont from The Faculty of Medical ... swell and stiffen when injected into a damaged area. ...
Cached Biology News:Researchers hot on the trail of brain cell degeneration 2Eating less salt could prevent cardiovascular disease 2Swell gel could bring relief to back pain sufferers 2
... The Chemicon Detergent-OUT SDS Kit is a ... from protein solutions. Removes detergents without ... load the protein solution on the Detergent-OUT ... solution. Med columns are suitable for ...
... from Paraffin embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 5 microns ... large (3-5 mm in diameter) in comparison ...
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5mm ...
... Precision-designed for Optimal Microdissection , CapSure HS ... precise and rapid extraction of populations of ... samples with Laser Capture Microdissection., Ensure ... Molecular Analysis , All CapSure LCM Caps ...
Biology Products: